

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
- NCAB asks for help from administration as NCI deals with deluge of grant applications
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home














